John Libbey Eurotext

Epileptic Disorders

The Educational Journal of the

Mega-dose phenobarbital therapy for super-refractory status epilepticus Volume 17, numéro 4, December 2015


  • Figure 1


Departments of Neurology, Laboratory for Neurotherapeutics, Comprehensive Epilepsy Center, Biomedical Research Institute,
1 Seoul National University Hospital,
2 Program in Neuroscience, Seoul National University College of Medicine, Seoul, South Korea
* Correspondence: Sang Kun Lee Department of Neurology, Seoul National University Hospital, 101 Daehang-ro, Chongro-gu, Seoul 110-744, South Korea
a Authors contributed equally.
  • Mots-clés : super-refractory status epilepticus, mega-dose phenobarbital, management, outcome
  • DOI : 10.1684/epd.2015.0778
  • Page(s) : 444-52
  • Année de parution : 2015


To evaluate the efficacy and safety of mega-dose phenobarbital (MDPB; enteral or parenteral phenobarbital >10 mg/kg/day) for treating super-refractory status epilepticus (SRSE; continuous or recurrent status epilepticus for ≥24 hours after the onset of continuous anaesthetic treatment) in adult patients.